Crescent Biopharma's Investigational New Drug Application for CR-002 to Treat Solid Tumors Cleared by FDA
MT newswire2026/10/05 12:2708:27 AM EDT, 10/05/2026 (MT Newswires) -- Crescent Biopharma (CBIO) said Monday that the US Food and Drug Administration cleared its Investigational New Drug application for CR-002, a potential treatment for advanced solid tumors. The clearance enables the oncology company to initiate the global phase 1/2 APOLLO trial, which is expected to enroll about 200 patients with advanced cancers, including non-small cell lung cancer, head and neck squamous cell carcinoma, and selected gastrointestinal and gynecological tumors. Initial clinical data are expected in the second half of 2027, including safety, pharmacokinetic and preliminary antitumor-activity results across multiple tumor types. Shares were up 1.5% premarket.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cybertruck orders far exceed pre-production capacity, Tesla (TSLA.US) to refund deposits to a large number of customers
Elon Musk stated that Tesla will refund the Cybertruck deposits to a significant number of customers.
Barrick Gold (B.US) Q3 Results Mixed: Benefiting from Gold Price Dividend While Facing Cost Pressures
Barrick Mining (B.US) will release its financial results for the third quarter of 2026 before the U.S. stock market opens on November 9.
Europe Becomes a Safe Haven Amid AI Turbulence! Citi Turns Bullish on European Stocks, Downgrades US Stocks: Low AI Exposure Seen as Key Advantage
Citigroup strategists have downgraded the rating of U.S. stocks and upgraded the rating of European stocks, following the recent market turbulence caused by upheaval in the artificial intelligence industry.
Rumor: Tesla (TSLA.US) and SpaceX (SPCX.US) plan Terafab monthly production of one million wafers, feasibility questioned
According to reports, Tesla (TSLA.US) and SpaceX (SPCX.US) plan to achieve a production capacity of 1 million semiconductor wafers per month at the proposed Terafab factory starting in 2032.
Crypto prices
More
